Kymera develops drugs that degrade disease-causing proteins.
Kymera Therapeutics, Inc. (KYMR) is expected to report earnings on Tuesday, November 3, 2026, before the open. Estimated release time 07:10 ET. Consensus EPS estimate is $-1.27.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | Jun 2026 qtr | $-0.71 | $-0.62 | +13.0% | $65.00M |
| 2026-04-30 | Mar 2026 qtr | $-0.89 | $-0.71 | — | — |
| 2025-08-11 | Jun 2025 qtr | $-0.83 | $-0.95 | -14.5% | $11.48M |
| 2025-05-09 | Mar 2025 qtr | $-0.92 | $-0.82 | +10.9% | $22.10M |
| 2025-02-27 | Dec 2024 qtr | $-0.76 | $-0.88 | — | $7.39M |
| 2024-08-07 | Jun 2024 qtr | $-0.69 | $-0.58 | — | $25.65M |
| 2024-05-02 | Mar 2024 qtr | $-0.73 | $-0.69 | +5.5% | $10.29M |
| 2024-02-22 | Dec 2023 qtr | $-0.44 | $-0.25 | — | $47.88M |
KYMR has beaten consensus EPS in 3 of its last 4 scored quarters.
See KYMR on the live calendar →